Eflumenibep alfa

依卢莫贝普α

Report date: 2026/04/16 20:00:17

Base Information

Drug NameEflumenibep alfa

Drug Alias NameFusion protein comprised of genetically engineered human serine peptidase inhibitor KAZAL Type 2 (SPINK2) and human immunoglobulin G (IgG) 1 Fc (Daiichi Sankyo)DS-2325-a

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein

Mechanisms of ActionAcrosin inhibitorsSerine protease inhibitor Kazal-type 2 replacement

TargetsAcrosinSerine protease inhibitor Kazal-type 2

Therapy Area/IndicationsNetherton Syndrome

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesFrance

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesDaiichi Sankyo Inc

China Registration ClassN/A

Develop Information

Active CompaniesDaiichi Sankyo Co Ltd

Inactive CompaniesN/A

Active IndicationsNetherton Syndrome

Inactive IndicationsN/A

Other Information

ATC CodeN/A